Advertisement

Current Atherosclerosis Reports

, Volume 10, Issue 5, pp 386–390 | Cite as

Triglycerides and risk for coronary artery disease

  • Patrick McBrideEmail author
Article

Abstract

Triglycerides (TGs) are now considered an independent risk factor for cardiovascular disease (CVD). When TGs are elevated, lipoprotein metabolism is altered, which increases CVD risk. Patients with elevated TGs and low high-density lipoprotein are at particularly high risk of CVD. TGs are often associated with other CVD risk factors, such as obesity, insulin resistance, diabetes mellitus, low HDL cholesterol, lifestyle factors, and changes in lipoprotein size and density. Elevated TGs remain an independent risk even when controlling for the other factors and are a greater risk for women than men. Treatment of elevated TGs in clinical trials has been shown to reduce CVD events, cardiac deaths, and total mortality.

Keywords

Atherogenic Lipoprotein Helsinki Heart Study Coronary Drug Project Familial Atherosclerosis Treatment Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jeppesen J, Hein HO, Suadicani P, et al.: Triglyceride concentration and ischemic heart disease. Circulation 1998, 97:1029–1036.PubMedGoogle Scholar
  2. 2.
    Hopkins PN, Wu LL, Hunt SC, Brinton EA: Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 2005, 45:1003–1012.PubMedCrossRefGoogle Scholar
  3. 3.
    Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Non-fasting triglycerides and risk of myocardial infarction, ischemic heart disease and death in the general population. JAMA 2007, 298:299–306.PubMedCrossRefGoogle Scholar
  4. 4.
    Bansal S, Buring JE, Rifai N, et al.: Fasting compared with non-fasting triglycerides and the risk of future cardiovascular events in women. JAMA 2007, 298:309–316.PubMedCrossRefGoogle Scholar
  5. 5.
    Tirosh A, Rudich A, Shochat T, et al.: Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med 2007, 147:377–385.PubMedGoogle Scholar
  6. 6.
    Patel A, Barzi F, Jamrozik K, et al.; Asia Pacific Cohort Studies Collaboration: Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004, 110:2678–2686.PubMedCrossRefGoogle Scholar
  7. 7.
    Austin MA: Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991, 11:2–14.PubMedGoogle Scholar
  8. 8.
    Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213–219.PubMedCrossRefGoogle Scholar
  9. 9.
    Sarwar N, Danesh J, Eiriksdottir G, et al.: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007, 115:450–458.PubMedCrossRefGoogle Scholar
  10. 10.
    Genest, JJ, Martin-Munley, SS, McNamara, JR, et al.: Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992, 85:2025.PubMedGoogle Scholar
  11. 11.
    Ginsberg HN: New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002, 106:2137–2142.PubMedCrossRefGoogle Scholar
  12. 12.
    St. Pierre AC, Ruel IL, Cantin B, et al.: Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001, 104:2295–2299.PubMedCrossRefGoogle Scholar
  13. 13.
    Otvos JD, Jeyarajah EJ, Cromwell WC: Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002, 90:22i–29i.PubMedCrossRefGoogle Scholar
  14. 14.
    Brehm A, Pfeiler G, Pacini G, et al.: Relationship with serum lipoprotein ratios and insulin resistance in obesity. Clin Chem 2004, 50:2316–2222.PubMedCrossRefGoogle Scholar
  15. 15.
    Gaziano JM, Hennekens CH, O’Donnell CJ, et al.: Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. 1997, 96:2520–2525.Google Scholar
  16. 16.
    Austin MA, King MC, Vranizan KM, et al.: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495–506.PubMedGoogle Scholar
  17. 17.
    Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998, 81:18B–25B.PubMedCrossRefGoogle Scholar
  18. 18.
    Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug Project patients: Long-term benefit of niacin. J Am Coll Cardiol 1986, 8:1245–1255.PubMedCrossRefGoogle Scholar
  19. 19.
    Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85:37–45.PubMedGoogle Scholar
  20. 20.
    Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585–1591.PubMedCrossRefGoogle Scholar
  21. 21.
    FIELD Study Investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849–1861.CrossRefGoogle Scholar
  22. 22.
    Miller M, Cannon CP, Murphy SA, et al.: Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724–730.PubMedCrossRefGoogle Scholar
  23. 23.
    Carlson LA, Rosenhammar G: Reduction of mortality in the Stockholm Ischemic Heart Disease Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405–418.PubMedGoogle Scholar
  24. 24.
    Superko HR, King S: Is lowering low-density lipoprotein an effective strategy to reduce cardiac risk? Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 2008, 117:560–568.PubMedCrossRefGoogle Scholar
  25. 25.
    National Cholesterol Education Panel: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–3421.Google Scholar
  26. 26.
    Sharett AR, Ballantyne CM, Coady SA, et al.: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-1 and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2001, 104:1108–1113.CrossRefGoogle Scholar
  27. 27.
    El Harchaoui K, van der Steeg WA, Stroes ESG, et al.: Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women. The EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 49:547–553.PubMedCrossRefGoogle Scholar
  28. 28.
    Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 2004, 27:2444–2449.PubMedCrossRefGoogle Scholar
  29. 29.
    Haim M, Benderly M, Brunner D, et al., for the BIP Study Group: Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) registry. Circulation 1999, 100:475–482.PubMedGoogle Scholar
  30. 30.
    Ingelsson E, Schaefer EJ, Contois JH, et al.: Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007, 298:776–785.PubMedCrossRefGoogle Scholar
  31. 31.
    Ridker PM, Rifai N, Cook NR, et al.: Non-HDL cholesterol, apoplipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 294:326–333.PubMedCrossRefGoogle Scholar
  32. 32.
    McBride PE: Triglycerides and risk for coronary heart disease. JAMA 2007, 298:336–338.PubMedCrossRefGoogle Scholar
  33. 33.
    Cui Y, Blumenthal RS, Flaws JA, et al.: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001, 161:1413–1419.PubMedCrossRefGoogle Scholar
  34. 34.
    Kontush A, Chapman MJ: Antiatherogenic small, dense HDL—guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006, 3:144–153PubMedCrossRefGoogle Scholar
  35. 35.
    Tribble DL, Holl LG, Wood PD, Krauss RM: Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1999, 93:189–199.CrossRefGoogle Scholar
  36. 36.
    Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69–75.PubMedGoogle Scholar
  37. 37.
    Sulkes D, Brown BG, Krauss RM, et al.: The Editors Roundtable: Expanded versus standard lipid panels in assessing and managing cardiovascular risk. Am J Cardiol 2008, 101:828–842.PubMedCrossRefGoogle Scholar
  38. 38.
    Mukamal KJ, Mackey RH, Kuller LH, et al.: Alcohol consumption and lipoprotein subclasses in older adults. J Clin Endocrinol Metab 2007, 92:2559–2566.PubMedCrossRefGoogle Scholar
  39. 39.
    Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289–1298.PubMedGoogle Scholar
  40. 40.
    Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.PubMedCrossRefGoogle Scholar
  41. 41.
    Brown BG, Brockenbrough A, Zhao XQ, et al.: Very intense lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up. Circulation 1998, 98(Suppl I):I–635.Google Scholar
  42. 42.
    Azen SP, Mack WJ, Cashin-Hemphill L, et al.: Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996, 93:34–41.PubMedGoogle Scholar
  43. 43.
    Carlson LA: Nicotinic acid: the broad-spectrum lipid drug: a 50th anniversary review. J Intern Med 2005, 258:94–114.PubMedCrossRefGoogle Scholar
  44. 44.
    AIM HIGH: Niacin Plus Statin to Prevent Vascular Events. Available at http://www.clinicaltrials.gov/ct/show/NCT00120289. Accessed on May 10, 2008.
  45. 45.
    Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al.: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996, 275:128–133.PubMedCrossRefGoogle Scholar
  46. 46.
    Guerin M, Egger P, Le Goff W, et al.: Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type iib hyperlipidemia. J Clin Endocrinol Metab 2002, 87:4991–5000PubMedCrossRefGoogle Scholar
  47. 47.
    Davidson MH, Ma P, Stein EA, et al.: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002, 89:268–275.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Preventive Cardiology ProgramUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations